The GIP/GLP-1 Revolution: Implications for Otolaryngology Practice

Saturday, October 17, 2026

1:00 PM - 2:00 PM PT

Location: 403B

Moderator(s)

EK

Erin M. Kirkham, MD MPH

Associate Professor, Otolaryngology-Head & Neck Surgery
University of Michigan
Ann Arbor, MI, United States

Panelist(s)

AM

Atul Malhotra, MD

Professor; Vice Chair of Medicine for Research; Research Chief of pulmonary, critical care, sleep
UCSD, United States
Eric J. Kezirian, MD, MPH

Professor-in-Residence
UCLA
Los Angeles, CA, United States
Alaina P. Vidmar, MD

Associate Professor of Clinical Pediatrics, Division of Pediatric Endocrlinology
Keck School of Medicine, University of Southern Califonria
Los Angeles, CA, United States

Disclosure(s):

Erin M. Kirkham, MD MPH:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Eric J. Kezirian, MD, MPH:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Alaina P. Vidmar, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Join experts from pediatric and adult otolaryngology, endocrinology, and sleep medicine for a practical guide to the "GIP/GLP-1 wave." Dr. Erin Kirkham will discuss the changing epidemiology of OSA in light of these new therapies. Dr. Alaina Vidmar (Pediatric Endocrinology) will discuss emerging data in youth. Dr. Atul Malhotra (PI, SURMOUNT-OSA) will translate pivotal adult trial data into clinical practice. Finally, Dr. Eric Kezirian will present a decision-making framework for integrating airway surgery with pharmacotherapy. The session concludes with a debate on management algorithms for increasingly common patient scenarios, and ample opportunity for audience questions.

Learning Objectives:

Interpret key clinical trial data for incretin-based therapies (e.g., tirzepatide) to identify optimal candidates among pediatric and adult patients with OSA.
Evaluate the distinct roles of medical versus surgical management in the era of potent pharmacotherapy, including timing for sleep endoscopy and airway surgery.
Implement a multidisciplinary counseling framework for patients who are GIP/GLP-1 inhibitor naïve, actively losing weight, or experiencing therapeutic plateaus.